Completed OBSERVATIONAL NCT01327339

REQUIP RLS Post Marketing Surveillance (REQUIP RLS PMS)

An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information

Sponsor: GlaxoSmithKline

Conditions Restless Legs Syndrome

Interventions Ropinirole

Updated 7 times since 2017 Last updated: Aug 14, 2017 Started: Apr 1, 2006 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Restless Legs Syndrome, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Oct 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Oct 2017 [monthly]

Completed NA

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.